Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis
Tricco AC, Antony J, Khan PA, Ghassemi M, Hamid JS, Ashoor H, Blondal E, Soobiah C, Yu CH, Hutton B, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open. 2014;4(12):e005752. doi: 10.1136/bmjopen-2014-005752.
[sidebar] Commissioned and funded by: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
[/no-bottom-margin]
Share Buttons [span][/span]
[ssba-buttons] [/sidebar] [sidebar-content]- Our results can be used by patients and physicians to tailor administration of these agents
- Conducted for the British Columbia Ministry of Health to inform the decision to delist DPP-4 inhibitors for type 2 diabetes patients in British Columbia
- DPP-4 inhibitors were superior to placebo in reducing HbA1c levels in adults with type 2 diabetes taking at least two oral agents. Compared with placebo, no safety signals were detected with DPP-4 inhibitors and there was a reduced risk of infection
- There was no significant difference in HbA1c observed between NPH and placebo or NPH and DPP-4 inhibitors
Almetrics:
Related Projects:
[/sidebar-content]Category : KS Projects
Date : 29 Oct 2019